Compare Novo Nordisk A/S (NVO) vs Vanguard Value Index Fund ETF (VTV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs Vanguard Value Index Fund ETF — how do they compare? Novo Nordisk A/S trades at $45.1 (market cap $200.69B), while Vanguard Value Index Fund ETF trades at $223.92. The key difference: Novo Nordisk A/S pays a 3.98% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | VTV | |
|---|---|---|
Market Cap | $200.69B | — |
Sector | Health | — |
52-Week High | $63.98 | $227.51 |
52-Week Low | $35.29 | $182.86 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% on the day, with a bearish technical outlook. The stock shows strong fundamentals, including a P/E of 11.07, net income margin of 35.35%, and consistent earnings beats. Recent news highlights the launch of Wegovy pill in Germany and positive pediatric obesity trial results, though competition with Eli Lilly remains intense.
The outlook is mixed: strong profitability and analyst buy consensus (57.9%) support upside, but technical weakness and competitive pressures pose risks. Revenue growth is steady, with 2026 projections at $329.4B, but recent trial halts for cardiovascular drugs dim diversification prospects.
VTV, the Vanguard Value ETF, trades at $224.64, down 0.8% on the day, with technical indicators showing a neutral overall signal amid mixed moving average and oscillator readings. The fund's value-focused strategy has outperformed growth counterparts in 2026, attracting institutional inflows, though key financial ratios are not individually disclosed for the ETF. A dividend of $1.08 is scheduled for June 2026.
The outlook for VTV is supported by the ongoing rotation into value stocks, with media highlighting its 2026 strength versus growth ETFs. Risks include potential underperformance if growth resumes leadership and fee-related long-term tracking differences noted in analysis. The neutral technical stance suggests near-term consolidation around current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About Vanguard Value Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →
